Oral Hypoglycemic Agents for Patients with Type 2 Diabetes Mellitus / 임상당뇨병
Journal of Korean Diabetes
; : 142-148, 2019.
Article
de Ko
| WPRIM
| ID: wpr-761491
Bibliothèque responsable:
WPRO
ABSTRACT
For patients with newly diagnosed type 2 diabetes mellitus (T2DM), lifestyle modifications including medical nutrition therapy, weight control, physical activity, smoking cessation, and avoidance of alcohol abuse should be initiated. Metformin must be considered as the first-line oral glucose-lowering therapy, but other drugs such as dipeptidyl peptidase 4 (DPP-4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, thiazolidinediones, glucagon-like peptide 1 receptor agonists, sulfonylureas, glinides, α-glucosidase inhibitors, and insulin can be considered based on patient circumstances. If the initial HbA1c level of a patient is ≥ 7.5% or the HbA1c target is not achieved within three months of initiating monotherapy, dual combination therapy can be considered. If the HbA1c target is not achieved within 3 months of initiating dual therapy, a third agent with a complementary mechanism of action can be added for triple combination therapy. In addition, evidence from large clinical studies assessing cardiovascular outcomes following the use of SGLT-2 inhibitors in T2DM patients with cardiovascular risk factors have been incorporated into the updated recommendations.
Mots clés
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Facteurs de risque
/
Arrêter de fumer
/
Dipeptidyl peptidase 4
/
Thiazolidinediones
/
Thérapie nutritionnelle
/
Diabète
/
Diabète de type 2
/
Alcoolisme
/
Glucagon-like peptide 1
/
Hypoglycémiants
Type d'étude:
Etiology_studies
/
Guideline
/
Risk_factors_studies
Limites du sujet:
Humans
langue:
Ko
Texte intégral:
Journal of Korean Diabetes
Année:
2019
Type:
Article